Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.47
Price to sales ratio
2.71

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2968
RLMD
Relmada Therapeutics, Inc. - Common Stock
4.33 USD-4.20%-6.68%-17.05%+283.19%461.88 M USD
2981
AGMB
AgomAb Therapeutics NV - ADRs representing one
13.17 USD-4.84%-0.30%+3.70%-10.41%449.98 M USD
2984
OCGN
Ocugen, Inc. - Common Stock
1.32 USD-3.65%-6.38%+8.20%+30.69%447.63 M USD
2988
RZLT
Rezolute, Inc. - Common Stock
4.62 USD-7.23%-8.15%-2.12%-35.11%444.87 M USD

Frequently asked questions about Ginkgo Bioworks Holdings, Inc.

What is the Ginkgo Bioworks Holdings, Inc. stock price today?

The current price of Ginkgo Bioworks Holdings, Inc. (DNA) is 6.98. Over the past 24 hours, the stock has changed by -3.99%. Follow the DNA chart for real-time price dynamics.

What is the stock ticker of Ginkgo Bioworks Holdings, Inc.?

Ginkgo Bioworks Holdings, Inc. trades under the ticker DNA. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Ginkgo Bioworks Holdings, Inc. stock going up?

DNA has changed by -4.12% over the last week, -10.40% over the last month, and -21.40% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Ginkgo Bioworks Holdings, Inc.?

Ginkgo Bioworks Holdings, Inc. currently has a market capitalization of 449.1 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Ginkgo Bioworks Holdings, Inc. earnings last quarter?

Last quarter, Ginkgo Bioworks Holdings, Inc. reported earnings of -0.75 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Ginkgo Bioworks Holdings, Inc. revenue for the last quarter?

Ginkgo Bioworks Holdings, Inc. reported quarterly revenue of 23.39 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Ginkgo Bioworks Holdings, Inc. net income for the last quarter?

Ginkgo Bioworks Holdings, Inc. reported net income of -46.71 M for the last quarter. The previous quarter showed -82.59 M, which means net income changed by +43.44%.

How many employees does Ginkgo Bioworks Holdings, Inc. have?

As of the latest available data, Ginkgo Bioworks Holdings, Inc. has 485 employees. Workforce size can provide additional context about the company's scale and operations.

What is Ginkgo Bioworks Holdings, Inc. EBITDA?

Ginkgo Bioworks Holdings, Inc. EBITDA is -51.22 M, and its EBITDA margin is -218.98%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Ginkgo Bioworks Holdings, Inc. stock?

You can buy Ginkgo Bioworks Holdings, Inc. (DNA) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Ginkgo Bioworks Holdings, Inc. stock?

Investing in Ginkgo Bioworks Holdings, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the DNA chart and related analysis on metatrader.com as part of your research.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

News